This Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855) provides $417,984 to the Scripps Research Institute to support a research project focused on the study of FOXP3 and regulatory T cell fate. The key objectives of the project are to: Identify the biomolecular target and mechanism of action for the small molecule A205804 in inducing functional CD4+ regulatory T cell differentiation...
This federal Project Grant award of $441,202.00 from the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855) aims to investigate the role of ex-regulatory T cells (ex-Tregs) in autoimmunity and anti-cancer immunity. The research will utilize a genetic Treg lineage tracing system to monitor ex-Tregs and deplete Tregs or both Tregs and ex-Tregs simultaneously. This will test the hypothesis that ex-Tregs are required...
This R03 project grant, awarded by the National Center for Advancing Translational Sciences (NCATS) under CFDA Program 93.350, aims to comprehensively identify metabolic enzymes that control the generation of TCF1+ progenitor CD8+ T cells, which are critical for durable anti-tumor immune responses. The $169,500 award, spanning from September 1, 2024 to August 31, 2026, will fund two key research objectives: Identifying metabolic enzymes whose loss alters T cell differentiation and the TCF1+...
This federal Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), is providing $162,512 to the Regents of the University of Minnesota to investigate the factors that support the expansion and function of long-lived effector CD8 T cells within the memory compartment. The key objectives are to determine what pro-inflammatory cytokines and other factors promote the formation and...
The National Institute of Allergy and Infectious Diseases (NIAID) awarded a $231,131 Project Grant under the Allergy and Infectious Diseases Research program (CFDA 93.855) to Duquesne University to develop an injectable 3D-clustered human fibroblastic reticular cell (FRC) formulation for expanding regulatory T cells (Tregs) to induce allograft transplant tolerance. The project aims to optimize the FRC formulation to generate Tregs in vitro and characterize the FRC cell depots' capacity to...
This Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), provides $709,019 to the Benaroya Research Institute at Virginia Mason to study the role of the FOXP3 isoform in regulating autoantibody production and the development of systemic lupus erythematosus (SLE). The key objectives are to: Determine the role of FOXP3E2-expressing regulatory T cells in germinal center function and the...
This five-year $196,992 Project Grant awarded by the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855) supports a research career development plan for Dr. Gloria Yiu, M.D., Ph.D., an Assistant Professor of Medicine in Rheumatology at the University of California, Los Angeles (UCLA). The key objectives of this research project are to: 1) enhance endogenous FOXP3 expression in induced pluripotent stem cells...
This Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855) will support research to investigate the role of the PPARD/CIITA/MHCII axis in regulating regulatory T cell (Treg) function and its impact on tumor immunity. The $276,450 award to the Salk Institute for Biological Studies will fund experiments to define the molecular mechanisms by which MHCII expression in Tregs is regulated by...
This Project Grant award, provided by the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847), focuses on investigating the role of lymph node stromal cells in maintaining peripheral tolerance and reducing autoimmunity in type 1 diabetes. The primary awardee, The Trustees of Columbia University in the City of New York, will receive $602,531 to conduct research aimed at: Evaluating...
This $1,559,700 Project Grant award from the National Institutes of Health (NIH) Office of the Director under the Trans-NIH Research Support program (CFDA 93.310) funds research by the Benaroya Research Institute at Virginia Mason (BRI) to investigate how genetic and epigenetic factors influence T cell function in autoimmune diseases. The key objectives are to: 1) use CRISPR-interference screening to identify regulatory regions that impact T cell proliferation and migration, 2) apply single-cell...
CLONAL ANALYSIS OF NATURALLY OCCURRING IL-10-PRODUCING TR1 CELLS - ABSTRACT THE DEVELOPMENT OF EFFECTIVE THERAPIES FOR THE TREATMENT OF T CELL-DEPENDENT AUTOIMMUNE DISEASES REQUIRES A LUCID UNDERSTANDING OF THE MECHANISMS BY WHICH T CELL TOLERANCE IS ESTABLISHED AND CONFERRED. IN MICE AND HUMANS, THE T CELL REPERTOIRE HARBORS SELF-REACTIVE CONVENTIONAL T CELLS WITH PATHOGENIC POTENTIAL, NECESSITATING EXTRINSIC REGULATION BY FOXP3-EXPRESSING REGULATORY T CELLS AND OTHER MECHANISMS. IN THIS REGARD, RESEARCH OVER THE PAST THREE DECADES HAS IDENTIFIED A UNIQUE CD4+ REGULATORY T CELL POPULATION, TERMED "TR1" CELLS, THAT IS CHARACTERIZED BY LACK OF FOXP3 EXPRESSION, PRODUCTION OF THE SUPPRESSIVE CYTOKINE IL-10, AND POTENT REGULATORY ACTIVITY CAPABLE OF PREVENTING OR STIFLING AUTOIMMUNE REACTIONS IN MURINE MODELS. IT HAS BEEN PROPOSED THAT TR1 CELLS SERVE AS A "FAILSAFE" IN SCENARIOS IN WHICH TOLERANCE MEDIATED BY FOXP3+ TREG CELLS IS INCOMPLETE. IMPORTANTLY, NUMEROUS STUDIES HAVE DEMONSTRATED THAT SUPPRESSIVE, ANTIGEN-SPECIFIC TR1-LIKE CELLS CAN BE GENERATED IN VITRO AND IN VIVO, GALVANIZING CONSIDERABLE INTEREST IN HARNESSING TR1 CELLS FOR THE CLINICAL TREATMENT OF HUMAN AUTOIMMUNE DISEASE. DESPITE THIS GREAT INTEREST, THERE REMAIN FUNDAMENTAL ASPECTS OF TR1 BIOLOGY THAT HAVE EVADED ELUCIDATION. IN THIS STUDY, WE WILL PERFORM CLONAL ANALYSIS OF NATURALLY OCCURRING TR1 (NTR1) CELLS IN MICE. WE WILL UTILIZE A TWO-TIERED STRATEGY PAIRING TCR REPERTOIRE PROFILING OF TR1-PHENOTYPE CELLS WITH CLONAL ANALYSES OF TCR "RETROGENIC" T CELLS EXPRESSING TR1-BIASED TCRS. THE OBJECTIVES OF THIS PROPOSAL ARE TO DEFINE THE NATURE OF THE TCR REPERTOIRE EXPRESSED BY NTR1 CELLS AND DEFINE THE DIFFERENTIATION TRAJECTORY, REACTIVITY, AND TRANSCRIPTIONAL PROFILE OF THESE CLONES IN VIVO AND IN VITRO. WE WILL TEST THE HYPOTHESIS THAT NTR1 CELL DIFFERENTIATION IS INITIATED IN THE THYMUS FOLLOWING THE RECOGNITION OF WIDESPREAD SELF-ANTIGENS, LEADING TO THE ESTABLISHMENT OF A STABLE PERIPHERAL POOL OF NTR1 CELLS EXPRESSING A DISTINCT TCR REPERTOIRE. IN AIM 1, WE WILL DEFINE THE TCR REPERTOIRE EXPRESSED BY NATURALLY OCCURRING TR1 CELLS. THIS WILL PROVIDE KEY INSIGHTS REGARDING THE DIVERSITY AND NATURE OF ANTIGENS THAT DIRECT NTR1 DIFFERENTIATION, THE STABILITY OF NTR1 CELLS, AND THE CLONAL RELATIONSHIP BETWEEN NTR1 CELLS AND OTHER T CELLS SUBSETS. IN AIM 2 WE WILL DETERMINE WHETHER NTR1 CELLS ARE REACTIVE TO WIDESPREAD SELF-ANTIGENS, REGIONAL SELF-ANTIGENS, OR ANTIGENS DERIVED FROM COMMENSAL MICROBIOTA, AND WILL DEFINE WHETHER NTR1 CELL DIFFERENTIATION IS TRIGGERED IN THE THYMUS OR PERIPHERY. IN ADDITION, WE WILL USE RNA SEQUENCING TO DEFINE UNIQUE SIGNATURES THAT DISTINGUISH NTR1 CELLS FROM OTHER REGULATORY AND CONVENTIONAL T CELL SUBSETS. OUR STUDIES WILL YIELD THE FIRST CLONAL ANALYSES OF NATURALLY OCCURRING IL-10-PRODUCING TR1 CELLS - AN IMPORTANT REGULATORY T CELL POPULATION FOR WHICH FUNDAMENTAL ASPECTS OF THEIR ANTIGEN SPECIFICITY, DIFFERENTIATION, LINEAGE STABILITY, AND FUNCTION REMAIN UNDEFINED. ULTIMATELY, THESE ADVANCES WILL BE CRUCIAL FOR THE DEVELOPMENT OF NEW STRATEGIES TO MOBILIZE NTR1 CELLS FOR THE TREATMENT OF HUMAN AUTOIMMUNE DISEASE.